Document is current
Any future updates will be listed below
-
Authors
Barwick, Tara D. https://orcid.org/0000-0002-9776-8766
Cyran, Clemens C. https://orcid.org/0000-0001-5630-6242
Mingels, Clemens https://orcid.org/0000-0001-6761-5323
van der Molen, Aart J. https://orcid.org/0000-0002-2376-9424
Aboagye, Eric O. https://orcid.org/0000-0003-2276-6771
- License Information
-
More Information
Article History
Received: 13 October 2025
Revised: 23 December 2025
Accepted: 28 January 2026
First Online: 6 April 2026
Compliance with ethical standards
:
: The scientific guarantors of this publication are Tara Barwick.
: E.O.A. was on the Scientific Advisory Board of Radiopharm Theranostics; EOA is the inventor of carboxylate imaging agents, including FPIA. Eric O. Aboagye is Board Chair of a recent Imperial College Spin-out involved in the commercialisation of [ 18 F]-FET-βAG-TOCA (FETO). Eric O. Aboagye and Tara Barwick acknowledge Institutional funding from GE Healthcare for clinical studies of GE226 affibody. The other coauthors declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
: No complex statistical methods were necessary for this paper.
: Not applicable.
: Institutional Review Board approval was not required.
: Not applicable.
:
